Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 157.26%.

  • ARS Pharmaceuticals' EBITDA Margin rose 7442800.0% to 157.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 56.3%, marking a year-over-year increase of 18363800.0%. This contributed to the annual value of 9.16% for FY2024, which is 1824191600.0% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its EBITDA Margin stood at 157.26% for Q3 2025, which was up 7442800.0% from 286.32% recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year EBITDA Margin high stood at 57.54% for Q4 2024, and its period low was 176180.0% during Q2 2023.
  • For the 4-year period, ARS Pharmaceuticals' EBITDA Margin averaged around 23896.61%, with its median value being 1093.51% (2022).
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -1747963800bps in 2023, then skyrocketed by 1736726000bps in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' EBITDA Margin (Quarter) stood at 3483.07% in 2022, then crashed by -4958bps to 176180.0% in 2023, then surged by 100bps to 57.54% in 2024, then plummeted by -373bps to 157.26% in 2025.
  • Its last three reported values are 157.26% in Q3 2025, 286.32% for Q2 2025, and 427.54% during Q1 2025.